INBS Intelligent Bio Solutions Inc. Total Debt to Capital

Intelligent Bio Solutions (INBS) is developing rapid fingerprint diagnostics, demonstrating success in Europe and Australia, although its US expansion awaits an FDA verdict. This chart reflects a market price of 0.35 as management implements non-invasive screening for law enforcement and employers. Large regional warehouses support business stability, guaranteeing the uninterrupted delivery of all necessary components.

Intelligent Bio Solutions (INBS) leverages unique biosensor patents to create significant barriers to entry for competitors, enabling the company to secure investments collateralized by intellectual assets. By analyzing the debt-to-equity chart, an investor assesses the proportion of liabilities per unit of equity to determine the business's financial stability and the risk of bankruptcy in the event of a decline in market capitalization.